S&P Futures
3,861.50 +13.25 (+0.34%) Dow Futures
31,115.00 +102.00 (+0.33%) Nasdaq Futures
11,935.25 +55.00 (+0.46%) Russell 2000 Futures
1,736.90 +8.30 (+0.48%) Crude Oil
99.15 +0.62 (+0.63%) Gold
1,744.60 +8.10 (+0.47%)
Dyadic International, Inc. (DYAI)
Chart Events
Performance Outlook
| Previous Close | 3.1500 |
| Open | 3.1900 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 1200 |
| Day's Range | 3.1500 - 3.2300 |
| 52 Week Range | 1.7400 - 6.8900 |
| Volume | |
| Avg. Volume | 59,511 |
| Market Cap | 91.011M |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4380 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DYAI
Related Research
- Dyadic International, Inc.Analyst Report: Charles River Laboratories IntCharles River Laboratories is a non-clinical contract research organization (CRO), providing drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, and the Asia Pacific region. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). CRL provides services in basic research, drug discovery, safety and efficacy assessment, clinical support, and manufacturing for a wide range of pharmaceutical and biotech customers. The company is headquartered in Wilmington, Massachusetts.RatingFair ValueEconomic Moat17 hours agoArgus Research
- GlobeNewswire
Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting
JUPITER, Fla., July 05, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary and patented microbial technologies to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, proteins, enzymes, certain metabolites and other biologic products at flexible commercial scales, today announced that its management an
- GlobeNewswire
Dyadic to Participate in Three Upcoming Industry Events
JUPITER, Fla., June 09, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1 protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and alternative food proteins and growth factors at flexible commercial scales, today announced that its management and representatives will
- GlobeNewswire
Dyadic to Present at 2022 Jefferies Healthcare Conference
JUPITER, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that its Chief Executive Officer, Mark Emalfarb will present at the 2022 Jefferies Heal
